**Background of ANGPTL6 Antibodies**
ANGPTL6 (angiopoietin-like protein 6), also known as angiopoietin-related growth factor (AGF), is a secreted glycoprotein belonging to the angiopoietin-like protein family. It is primarily expressed in the liver and endothelial cells, playing roles in metabolic regulation, angiogenesis, and tissue repair. Structurally, ANGPTL6 contains an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain, enabling interactions with extracellular receptors to modulate signaling pathways.
Research highlights its dual functions: promoting energy expenditure to combat obesity and enhancing insulin sensitivity, while also stimulating vascular growth in contexts like tissue injury or tumorigenesis. Dysregulation of ANGPTL6 is linked to metabolic disorders, cardiovascular diseases, and cancer progression.
ANGPTL6 antibodies are tools developed to study the protein's expression, localization, and mechanistic roles. They are used in immunoassays (e.g., ELISA, Western blot, immunohistochemistry) to quantify ANGPTL6 levels in biological samples or block its activity in functional studies. Therapeutic potential is also explored; neutralizing antibodies may inhibit ANGPTL6-driven pathways in metabolic syndromes or cancer. However, challenges remain in understanding tissue-specific functions and optimizing antibody specificity for clinical applications. Current studies focus on clarifying its physiological and pathological impacts to guide targeted therapies.